Novo Nordisk A/S (NVO) Stock Forecast & Price Target
Price as of Nov 17, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 11, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Novo Nordisk A/S (NVO), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Novo Nordisk A/S, analysts forecast revenue rising from DKK 307.98B in 2025 to DKK 376.12B in 2030; the average estimate for 2030 earnings per share is DKK 29.16; with published estimates ranging from DKK 27.16 to DKK 31.78; 16 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (DKK)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast (DKK)
Novo Nordisk A/S (NVO) forecast — frequently asked questions
What is the analyst price target for Novo Nordisk A/S?
Analysts covering Novo Nordisk A/S (NVO) have a consensus price target of $42.33, 4.4% above the current price of $40.56. Published targets range from $40.00 to $47.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Novo Nordisk A/S's earnings?
The average analyst estimate for Novo Nordisk A/S (NVO) earnings per share in 2030 is 29.16, with individual estimates between 27.16 and 31.78.
How much revenue is Novo Nordisk A/S expected to make?
Analysts forecast Novo Nordisk A/S (NVO) revenue of DKK 376.12B in 2030, based on 7 published estimates.
How many analysts cover NVO?
16 analysts contribute estimates for Novo Nordisk A/S (NVO). Thin coverage makes an average less reliable.
Analyst forecasts for other Drug Manufacturers - General stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.